← Back to Screener
Lineage Cell Therapeutics, Inc. (LCTX)
Price$1.26
Value ScoreC
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-36.29%
Price vs S&P 500 (4W)-18.04%
VGM Score45.15
Market Capitalization$331.57M
All Metrics
Book Value / Share (Quarterly)$0.22
P/TBV (Annual)29.94x
Revenue Growth (3Y)61.12%
Cash Flow / Share (Quarterly)$-0.09
Price vs S&P 500 (YTD)-31.29%
Gross Margin (TTM)94.11%
Net Profit Margin (TTM)-431.16%
EPS (TTM)$-0.28
10-Day Avg Trading Volume1.05M
EPS Excl Extra (TTM)$-0.28
Revenue Growth (5Y)33.57%
EPS (Annual)$-0.28
ROI (Annual)-142.39%
Gross Margin (Annual)92.50%
Net Profit Margin (5Y Avg)-506.99%
Cash / Share (Quarterly)$0.21
Revenue Growth QoQ (YoY)15.00%
ROA (Last FY)-56.43%
Revenue Growth TTM (YoY)-37.15%
EBITD / Share (TTM)$-0.16
ROE (5Y Avg)-28.77%
Operating Margin (TTM)-256.54%
Cash Flow / Share (Annual)$-0.08
P/B Ratio6.15x
P/B Ratio (Quarterly)7.30x
Net Income / Employee (Annual)$-882,400
EV / Revenue (TTM)22.43x
Net Interest Coverage (TTM)-17.84x
ROA (TTM)-63.31%
EV / EBITDA (TTM)7.66x
EPS Incl Extra (Annual)$-0.28
Current Ratio (Annual)5.20x
Quick Ratio (Quarterly)6.65x
3-Month Avg Trading Volume1.20M
52-Week Price Return92.75%
Revenue / Employee (TTM)$205,300
Tangible BV / Share (Quarterly)$0.09
P/S Ratio (Annual)37.07x
Asset Turnover (Annual)0.09x
52-Week High$2.09
Operating Margin (5Y Avg)-339.82%
EPS Excl Extra (Annual)$-0.28
CapEx CAGR (5Y)-20.81%
Tangible BV CAGR (5Y)-36.58%
26-Week Price Return-20.36%
Quick Ratio (Annual)4.99x
13-Week Price Return-32.14%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.89x
Enterprise Value$331.62M
Revenue / Share Growth (5Y)23.45%
Asset Turnover (TTM)0.15x
Book Value / Share Growth (5Y)-19.58%
Revenue / Employee (Annual)$124,200
Inventory Turnover (Annual)7.40x
Pretax Margin (Annual)-260.28%
Cash / Share (Annual)$0.23
3-Month Return Std Dev53.52%
Gross Margin (5Y Avg)88.93%
Net Income / Employee (TTM)$-885,300
ROE (Last FY)-142.61%
Net Interest Coverage (Annual)-16.50x
EPS Basic Excl Extra (Annual)$-0.28
P/FCF (TTM)14.83x
Receivables Turnover (TTM)20.26x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.28
Receivables Turnover (Annual)0.58x
ROI (TTM)-151.07%
P/S Ratio (TTM)22.43x
Pretax Margin (5Y Avg)-535.76%
Revenue / Share (Annual)$0.05
Tangible BV / Share (Annual)$0.05
Free OCF CAGR (5Y)-38.10%
Price vs S&P 500 (52W)64.55%
EPS Growth TTM (YoY)53.54%
Year-to-Date Return-20.36%
5-Day Price Return2.31%
EPS Normalized (Annual)$-0.28
ROA (5Y Avg)-22.63%
Net Profit Margin (Annual)-240.20%
Month-to-Date Return-11.92%
Cash Flow / Share (TTM)$-0.13
EBITD / Share (Annual)$-0.16
Operating Margin (Annual)-276.50%
LT Debt / Equity (Annual)0.11x
ROI (5Y Avg)-25.56%
LT Debt / Equity (Quarterly)0.14x
EPS Basic Excl Extra (TTM)$-0.28
P/TBV (Quarterly)17.75x
P/B Ratio (Annual)8.63x
Inventory Turnover (TTM)7.40x
Pretax Margin (TTM)-466.24%
Book Value / Share (Annual)$0.18
Price vs S&P 500 (13W)-41.89%
Beta1.48x
P/FCF (Annual)262.32x
Revenue / Share (TTM)$0.06
ROE (TTM)-151.35%
52-Week Low$0.64
vGradeC
gGradeC
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.03est. -0.02
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.08
4.08
4.08
4.07
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LCTXLineage Cell Therapeutics, Inc. | C | C | C | $1.26 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell replacement and cell/drug delivery therapies for degenerative diseases. Key pipeline candidates include OpRegen for age-related macular degeneration, OPC1 for spinal cord injuries, VAC2 for non-small cell lung cancer, and cell therapies for hearing and vision loss.